Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong, with no signs of business deterioration. Despite Eli Lilly's underperformance in GLP-1 sales ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy ...

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

Novo Nordisk A/S Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company’s weight loss and diabetes drugs Wegovy and ...

McDonald is global head of business development and M&A at Novo Nordisk, a company that was one of the top dealmakers in 2023, striking 14 transactions totaling $9.5 billion in disclosed deal value.

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...